These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 25245127)
41. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O; Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881 [TBL] [Abstract][Full Text] [Related]
42. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer. Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600 [TBL] [Abstract][Full Text] [Related]
43. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study. Alyami M; Lundberg P; Kepenekian V; Goéré D; Bereder JM; Msika S; Lorimier G; Quenet F; Ferron G; Thibaudeau E; Abboud K; Lo Dico R; Delroeux D; Brigand C; Arvieux C; Marchal F; Tuech JJ; Guilloit JM; Guyon F; Peyrat P; Pezet D; Ortega-Deballon P; Zinzindohoue F; de Chaisemartin C; Kianmanesh R; Glehen O; Passot G; Ann Surg Oncol; 2016 Dec; 23(Suppl 5):737-745. PubMed ID: 27600619 [TBL] [Abstract][Full Text] [Related]
44. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Sardi A; Jimenez W; Nieroda C; Sittig M; Shankar S; Gushchin V Ann Surg Oncol; 2014 Mar; 21(3):908-14. PubMed ID: 24276642 [TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
46. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929 [TBL] [Abstract][Full Text] [Related]
47. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583 [TBL] [Abstract][Full Text] [Related]
48. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
49. Preoperative Nutrition Status and Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Reece L; Dragicevich H; Lewis C; Rothwell C; Fisher OM; Carey S; Alzahrani NA; Liauw W; Morris DL Ann Surg Oncol; 2019 Aug; 26(8):2622-2630. PubMed ID: 31123932 [TBL] [Abstract][Full Text] [Related]
50. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ahmed S; Levine EA; Randle RW; Swett KR; Shen P; Stewart JH; Votanopoulos KI Ann Surg Oncol; 2014 Dec; 21(13):4226-31. PubMed ID: 25034815 [TBL] [Abstract][Full Text] [Related]
51. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
52. Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Alyami M; Kim BJ; Villeneuve L; Vaudoyer D; Képénékian V; Bakrin N; Gilly FN; Cotte E; Glehen O; Passot G Int J Hyperthermia; 2018 Aug; 34(5):532-537. PubMed ID: 28838265 [TBL] [Abstract][Full Text] [Related]
53. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study. Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037 [TBL] [Abstract][Full Text] [Related]
54. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870 [TBL] [Abstract][Full Text] [Related]
55. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Squires MH; Staley CA; Knechtle W; Winer JH; Russell MC; Perez S; Sweeney JF; Maithel SK; Staley CA Ann Surg Oncol; 2015 May; 22(5):1739-45. PubMed ID: 25249258 [TBL] [Abstract][Full Text] [Related]
56. Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. Liu Y; Endo Y; Fujita T; Ishibashi H; Nishioka T; Canbay E; Li Y; Ogura S; Yonemura Y Ann Surg Oncol; 2014 Dec; 21(13):4256-62. PubMed ID: 25056850 [TBL] [Abstract][Full Text] [Related]
57. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324 [TBL] [Abstract][Full Text] [Related]
58. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829 [TBL] [Abstract][Full Text] [Related]
59. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450 [TBL] [Abstract][Full Text] [Related]
60. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]